Israel Englander Genprex, Inc. Transaction History

Millennium Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.19 - $0.37 $5,362 - $10,443	28,226 New	28,226 $6,000
Q4 2022 Feb 14, 2023	SELL	$1.0 - $58.8 $112,201 - $6.6 Million	-112,201 Reduced 78.04%	31,569 $46,000
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $19,546 - $858,864	14,808 Added 11.48%	143,770 $203,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $109,498 - $197,611	-85,546 Reduced 39.88%	128,962 $179,000
Q1 2022 May 16, 2022	SELL	$1.82 - $3.5 $418,505 - $804,818	-229,948 Reduced 51.74%	214,508 $485,000
Q4 2021 Feb 14, 2022	BUY	$1.21 - $2.7 $144,770 - $323,041	119,645 Added 36.84%	444,456 $582,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $3.36 $405,821 - $526,471	-156,688 Reduced 32.54%	324,811 $870,000
Q2 2021 Aug 16, 2021	BUY	$3.11 - $4.87 $1.1 Million - $1.73 Million	354,669 Added 279.64%	481,499 $1.61 Million
Q1 2021 May 17, 2021	BUY	$3.66 - $7.67 $464,197 - $972,786	126,830 New	126,830 $547,000
Q2 2020 Aug 14, 2020	SELL	$1.99 - $3.64 $86,678 - $158,547	-43,557 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$0.28 - $6.23 $12,195 - $271,360	43,557 New	43,557 $105,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.